본문으로 건너뛰기
← 뒤로

Applying next-generation sequencing to predict short progression-free survival in patients with advanced EGFR -mutant lung adenocarcinoma receiving epidermal growth factor receptor tyrosine kinase inhibitors.

Anti-cancer drugs 2025 Vol.36(10) p. 839-845

Lee PH, Hsiao YC, Huang YH, Hsu KH, Tseng JS, Lin H, Chang GC, Yang TY

📝 환자 설명용 한 줄

For patients with advanced EGFR -mutant lung adenocarcinoma, progression-free survival (PFS) is significantly improved by epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) medicati

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • p-value P  = 0.006
  • p-value P  = 0.010

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Lee PH, Hsiao YC, et al. (2025). Applying next-generation sequencing to predict short progression-free survival in patients with advanced EGFR -mutant lung adenocarcinoma receiving epidermal growth factor receptor tyrosine kinase inhibitors.. Anti-cancer drugs, 36(10), 839-845. https://doi.org/10.1097/CAD.0000000000001762
MLA Lee PH, et al.. "Applying next-generation sequencing to predict short progression-free survival in patients with advanced EGFR -mutant lung adenocarcinoma receiving epidermal growth factor receptor tyrosine kinase inhibitors.." Anti-cancer drugs, vol. 36, no. 10, 2025, pp. 839-845.
PMID 40773366

Abstract

For patients with advanced EGFR -mutant lung adenocarcinoma, progression-free survival (PFS) is significantly improved by epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) medications. However, a subset of patients still experiences early disease progression. In this study, we aimed to identify potential risk factors associated with shorter PFS through next-generation sequencing (NGS) analysis. This retrospective study included patients with advanced EGFR -mutant lung adenocarcinoma who received first-line EGFR-TKI treatment with upfront NGS. The genetic alterations included two types, mutations and copy number variations. Alterations involving EGFR downstream signaling pathways were classified as ' PIK3CA-AKT/RAS-RAF alterations'. Clinical and histopathological data were also collected and analyzed. We studied a total of 82 advanced lung cancer patients with sensitive EGFR mutations. Multivariable analyses showed associations with a shorter PFS for the following factors: P IK3CA-AKT/RAS-RAF alterations [hazard ratio (HR) 3.197, P  = 0.006], age ≤50 (HR 3.034, P  = 0.010), and PD-L1 ≥50% (HR 2.256, P  = 0.035). Based on the above risk factors, patients were classified into no-risk and ≥1 risk groups. In the no-risk group, third-generation EGFR-TKIs showed a numerically longer PFS compared to first/second-generation EGFR-TKIs (not reached vs. 20.0 months, P  = 0.084). However, in patients with ≥1 risk factor, third-generation EGFR-TKIs showed no PFS advantages (6.6 vs. 6.2 months, P  = 0.831). In conclusion, besides clinicopathological factors, NGS provides additional insights to predict shorter PFS after EGFR-TKI treatment. We identified three risk factors: (1) PIK3CA-AKT/RAS-RAF alterations, (2) age ≤50, and (3) PD-L1 ≥50%. Patients with these factors had poor PFS regardless of EGFR-TKI generation.

MeSH Terms

High-Throughput Nucleotide Sequencing; Progression-Free Survival; Time Factors; ErbB Receptors; Mutation; Adenocarcinoma of Lung; Lung Neoplasms; Tyrosine Kinase Inhibitors; DNA Copy Number Variations; Risk Factors; Kaplan-Meier Estimate; Humans; Male; Female; Middle Aged; Aged; Antineoplastic Agents; Follow-Up Studies; Retrospective Studies; Age Factors